Evidence map›Paper›PMID 38773000›Full record

ArticleJournal of clinical immunology2024

Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity.

Satoshi Miyamoto, Daiki Niizato, Dan Tomomasa, Akira Nishimura, Akihiro Hoshino, Takahiro Kamiya, Takeshi Isoda, Masatoshi Takagi, Michiko Kajiwara, Shohei Azumi and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Satoshi MiyamotoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Daiki NiizatoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Dan TomomasaDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Akira NishimuraDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Akihiro HoshinoDepartment of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Takahiro KamiyaDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Takeshi IsodaDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Masatoshi TakagiDepartment of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Michiko KajiwaraCenter for Transfusion Medicine and Cell Therapy, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
Shohei AzumiDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Shinsuke HirabayashiDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Kenichi SakamotoDepartment of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
Kenji KishimotoDepartment of Hematology and Oncology, Kobe Children's Hospital, Hyogo, Japan.
Takako MiyamuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Katsutsugu UmedaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ayana HiroseDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Dai KeinoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Masakatsu YanagimachiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Kaori KandaDepartment of Pediatrics, Gifu Municipal Hospital, Gifu, Japan.
Yuta SakaiDepartment of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Yasuhiro IkawaDepartment of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Kenichiro WatanabeDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Keisuke TanakaDepartment of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Takehiko MoriDepartment of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Hirotoshi SakaguchiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Tomohiro MorioDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Hirokazu KaneganeDepartment of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. hkanegane.ped@tmd.ac.jp.

Funding

MEXT/JSPS KAKENHI 22K07887
6 · The paper itself

Abstract

Alemtuzumab is used with reduced-toxicity conditioning (RTC) in allogeneic hematopoietic cell transplantation (HCT), demonstrating efficacy and feasibility for patients with inborn errors of immunity (IEI) in Western countries; however, the clinical experience in Asian patients with IEI is limited. We retrospectively analyzed patients with IEI who underwent the first allogeneic HCT with alemtuzumab combined with RTC regimens in Japan. A total of 19 patients were included and followed up for a median of 18 months. The donors were haploidentical parents (n = 10), matched siblings (n = 2), and unrelated bone marrow donors (n = 7). Most patients received RTC regimens containing fludarabine and busulfan and were treated with 0.8 mg/kg alemtuzumab with intermediate timing. Eighteen patients survived and achieved stable engraftment, and no grade 3-4 acute graft-versus-host disease was observed. Viral infections were observed in 11 patients (58%) and 6 of them presented symptomatic. The median CD4

Indexed as

AlemtuzumabGraft vs Host DiseaseHematopoietic Stem Cell TransplantationTransplantation ConditioningTransplantation, HomologousAdolescentChildChild, PreschoolEast Asian PeopleFemaleHumansImmune System DiseasesInfantJapanMaleRetrospective StudiesAlemtuzumabAlemtuzumabAsianHematopoietic cell transplantationInborn errors of immunityRetrospective study

Identifiers

PMID38773000

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.